Literature DB >> 19875977

Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion.

Seunggu J Han1, Brian J Ahn, James S Waldron, Isaac Yang, Shanna Fang, Courtney A Crane, Russell O Pieper, Andrew T Parsa.   

Abstract

B7 homolog 1 (B7-H1) is a recently discovered immunoresistance protein that is regulated posttranscriptionally after PTEN loss in malignant glioma, a deadly form of brain tumor. Here, the impact of gamma-interferon-mediated activation of B7-H1 was investigated in glioblastoma patients with PTEN loss. Lymphocytes and T cells were selected for apoptosis assays after 1 : 1 coculture with autologous glioma cells. Gamma interferon treatment of PTEN-deficient tumors resulted in superinduction of B7-H1 protein that correlated with increased T-cell apoptosis, an effect dependent upon activation of the PI3-kinase pathway. The combination of PTEN loss and gamma-interferon exposure in glioblastoma patients results in an exceptionally immunoresistant phenotype that may negate adaptive immunity through induction of T-cell apoptosis.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19875977      PMCID： PMC3666317          DOI： 10.1097/WNR.0b013e32833188f7

Source DB:  PubMed          Journal:  Neuroreport        ISSN： 0959-4965            Impact factor:   1.837


  16 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

Review 2.  The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.

Authors:  M Weller; A Fontana
Journal:  Brain Res Brain Res Rev       Date:  1995-09

3.  Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme.

Authors:  Isaac Yang; Thomas J Kremen; Adrian J Giovannone; Elena Paik; Sylvia K Odesa; Robert M Prins; Linda M Liau
Journal:  J Neurosurg       Date:  2004-02       Impact factor: 5.115

Review 4.  B7-H1 pathway and its role in the evasion of tumor immunity.

Authors:  Haidong Dong; Lieping Chen
Journal:  J Mol Med (Berl)       Date:  2003-04-30       Impact factor: 4.599

5.  In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis.

Authors:  Aurore Saudemont; Bruno Quesnel
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113

6.  Transcriptional responses of murine macrophages to infection with Yersinia enterocolitica.

Authors:  Reinhard Hoffmann; Katrin van Erp; Konrad Trülzsch; Jürgen Heesemann
Journal:  Cell Microbiol       Date:  2004-04       Impact factor: 3.715

7.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

8.  Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function.

Authors:  Courtney Crane; Amith Panner; Russell O Pieper; Jack Arbiser; Andrew T Parsa
Journal:  J Immunother       Date:  2009 Jul-Aug       Impact factor: 4.456

9.  Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis.

Authors:  Sabine Wintterle; Bettina Schreiner; Meike Mitsdoerffer; Dagmar Schneider; Lieping Chen; Richard Meyermann; Michael Weller; Heinz Wiendl
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

10.  PTEN methylation and expression in glioblastomas.

Authors:  Nathalie Baeza; Michael Weller; Yasuhiro Yonekawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Acta Neuropathol       Date:  2003-08-02       Impact factor: 17.088
View more
  23 in total

Review 1.  The Safety of available immunotherapy for the treatment of glioblastoma.

Authors:  S Harrison Farber; Aladine A Elsamadicy; Ahmet Fatih Atik; Carter M Suryadevara; Pakawat Chongsathidkiet; Peter E Fecci; John H Sampson
Journal:  Expert Opin Drug Saf       Date:  2017-01-03       Impact factor: 4.250

2.  Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.

Authors:  Szu-Ting Chou; Rameshwar Patil; Anna Galstyan; Alexander V Ljubimov; Julia Y Ljubimova; Pallavi R Gangalum; Webster K Cavenee; Frank B Furnari; Vladimir A Ljubimov; Alexandra Chesnokova; Andrei A Kramerov; Hui Ding; Vida Falahatian; Leila Mashouf; Irving Fox; Keith L Black; Eggehard Holler
Journal:  J Control Release       Date:  2016-11-05       Impact factor: 9.776

3.  Tumor immune microenvironment is associated with the growth of intracranial germinomas.

Authors:  Masaaki Nishimoto; Kentaro Ohara; Dai Kamamoto; Ryota Tamura; Tomoru Miwa; Kazunari Yoshida; Hikaru Sasaki
Journal:  J Neurooncol       Date:  2019-11-26       Impact factor: 4.130

Review 4.  PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.

Authors:  Taemin Oh; Michael E Ivan; Matthew Z Sun; Michael Safaee; Shayan Fakurnejad; Aaron J Clark; Eli T Sayegh; Orin Bloch; Andrew T Parsa
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

5.  Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.

Authors:  Dai Kamamoto; Kentaro Ohara; Yohei Kitamura; Kazunari Yoshida; Yutaka Kawakami; Hikaru Sasaki
Journal:  J Neurooncol       Date:  2018-04-19       Impact factor: 4.130

Review 6.  The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.

Authors:  Andrew S Luksik; Russell Maxwell; Tomas Garzon-Muvdi; Michael Lim
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 7.  Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.

Authors:  Lauren C Harshman; Toni K Choueiri; Charles Drake; F Stephen Hodi
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

Review 8.  Vaccine-based immunotherapy for glioblastoma.

Authors:  Alissa A Thomas; Jan L Fisher; Marc S Ernstoff; Camilo E Fadul
Journal:  CNS Oncol       Date:  2013-07

9.  Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.

Authors:  Fernando Concha-Benavente; Raghvendra M Srivastava; Sumita Trivedi; Yu Lei; Uma Chandran; Raja R Seethala; Gordon J Freeman; Robert L Ferris
Journal:  Cancer Res       Date:  2015-12-16       Impact factor: 12.701

Review 10.  Immunotherapy advances for glioblastoma.

Authors:  David A Reardon; Gordon Freeman; Catherine Wu; E Antonio Chiocca; Kai W Wucherpfennig; Patrick Y Wen; Edward F Fritsch; William T Curry; John H Sampson; Glenn Dranoff
Journal:  Neuro Oncol       Date:  2014-09-04       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.